NPJ precision oncology
Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.
Matthew Lee, Junmin Song, Emily Miao, Daniel S Alicea, Chenxin Zhang, Xiaonan Xue, Steven Tuckman, Jihua Yang, Angelica D'Aiello, Rasim Gucalp, Brendon Stiles, Nitin Ohri, Balazs Halmos, Haiying Cheng
Published: 202610.1038/s41698-025-01259-z
Abstract
Osimertinib has been one of the most commonly prescribed first-line treatments for EGFR-mutated advanced NSCLC for the last several years for patients with EGFR-mutated non-small cell lung cancer (NSCLC), yet clinical outcomes among racial and ethnic…
Preview only. Read the full abstract at the source